CytoDyn, Inc. has selected the Waisman Clinical BioManufacturing Facility (WCBF) at the University of Wisconsin at Madison to manufacture its DNA-based pre-flu vaccine. The pre-flu vaccine provides an alternative approach to immunization that could enhance the efficacy of flu vaccines for seasonal flu and bird flu. It uses DNA technology to implant a false memory of previous exposure to the flu virus, including the inactivated virus contained in standard vaccines. The company hopes to have clini...